Contact Points
The National Center for Advancing Translational Sciences (NCATS) requires the testing of forty-three (43) compounds against the AKT1 and LATS1 compounds in a NanoBRET Target Engagement Intracellular Kinase Assay. This testing will inform on kinase inhibitory activity in our compound series, and will facilitate further optimization and development of these AKT1 / LATS1 compounds as well as potential treatments.
The contractor will be required to:
1. Test 43 compounds against the AKT1 and LATS1 compounds in a NanoBRET target Engagement Intracellular Kinase Assay.
2. Provide a comprehensive report with the results of the experiments of each of the 43 compounds against AKT1 and LATS1. The report is to be submitted electronically to NCATS within 60 days after receiving the compounds for testing.
NCATS will provide sufficient quantities of the lead compounds in order to contractor to accomplish the requiremens described above. NCATS anticipates sending the compounds to the contractor shortly after contract award.
Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.
All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.